Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2128

A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer

9:00AM-11:00AM: Abstract Number: 2100

An International Consensus Exercise to Develop Candidate Items for Classification Criteria in Relapsing Polychondritis

9:00AM-11:00AM: Abstract Number: 2111

Anti-N-Methyl-D-Aspartate Receptor Encephalitis – Expanding Our Understanding of the Clinical Needs of Pediatric Patients with This Complex Disorder

9:00AM-11:00AM: Abstract Number: 2112

Anti-TNFα Versus Rituximab in Refractory Peripheral Ulcerative Keratitis Associated to Rheumatic Diseases. Multicenter Study of 24 Patients

9:00AM-11:00AM: Abstract Number: 2122

Association of Retroperitoneal Fibrosis with Malignancy

9:00AM-11:00AM: Abstract Number: 2118

Asymptomatic Tendinitis of Flexor Digitorum Tendons in Patients with Type 2 Diabetes : A Single-Center, Cross-Sectional Prevalence Study

9:00AM-11:00AM: Abstract Number: 2121

Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies

9:00AM-11:00AM: Abstract Number: 2110

Blood Group ”a“ Was Increased in FMF Patients and Blood Group ”0“ May be Associated with Colchicine Resistance

9:00AM-11:00AM: Abstract Number: 2117

C-Reactive Protein and Serum Amyloid a in Sepsis, Acute Appendicitis and Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 2097

Clinical Significance of KL-6 and SP-D As Serum Markers for Interstitial Lung Disease in Patients with Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2108

Colchicine Treatment May be Protective Against Ventricular Arrhythmias in FMF Patients

9:00AM-11:00AM: Abstract Number: 2093

Comparison of Clinical and Laboratory Features of Patients with and without Allergic Conditions in IgG4-Related Disease: A Single-Center Experience in Japan

9:00AM-11:00AM: Abstract Number: 2099

Elderly – Onset Sarcoidosis: a Single Center Comparative Study

9:00AM-11:00AM: Abstract Number: 2105

Epidemiology of Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 2116

Evaluation of Connective Tissue Diseases in Patients Presenting with Interstitial Lung Disease in a Referral Center in Santiago, Chile

9:00AM-11:00AM: Abstract Number: 2129

Evaluation of Suppurative Hidradenitis in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2104

Exposure to Fine Particle Air Pollution and Anti-Nuclear Antibodies (ANA) in a Large Population-Based Sample

9:00AM-11:00AM: Abstract Number: 2113

Familial Mediterranean Fever in Chinese Adult Patients

9:00AM-11:00AM: Abstract Number: 2109

Hyperferritinemic Syndrome in a General Hospital

9:00AM-11:00AM: Abstract Number: 2125

Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 2106

Immune-Related Adverse Events in Cancer Patients Treated with Immune Check Point Inhibitors: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2114

Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?

9:00AM-11:00AM: Abstract Number: 2115

Mast Cell Activation Features in Ehlers-Danlos/Joint Hypermobility Patients: A Retrospective Analysis in Light of an Emerging Disease Cluster

9:00AM-11:00AM: Abstract Number: 2124

Mixed Connective Tissue Disorder Has Higher Prevalence of Arthritis and Use of Methotrexate Than Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2096

Nailfold Capillaroscopy Is an Opportunity for Telerheumatology

9:00AM-11:00AM: Abstract Number: 2092

Pilot Clinical Study of a Novel Unobtrusive Carpal Tunnel Tissue Manipulation Device in Reducing Symptoms of Carpal Tunnel Syndrome

9:00AM-11:00AM: Abstract Number: 2094

Prevalence of Organ Involvement in Mixed Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2103

Problems in the Diagnosis of Familial Mediterranean Fever in Turkey

9:00AM-11:00AM: Abstract Number: 2123

Protein-Losing Enteropathy in Patients with Systemic Autoimmune Diseases: Characterization of 263 Cases (GEAS-SEMI Spanish Cohort)

9:00AM-11:00AM: Abstract Number: 2120

Quality, Content and Readability Assessment of Patient Education Websites Relating to Ehlers-Danlos Syndrome

9:00AM-11:00AM: Abstract Number: 2119

Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

9:00AM-11:00AM: Abstract Number: 2126

Safety of Immune Checkpoint Inhibitors for the Treatment of Melanoma, Bronchopulmonary and Urologic Neoplasms in Patients with Preexisting Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 2098

Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 2101

The Clinical Characteristics of IgG4 Related Disease in China: With 346 Cases Reported

9:00AM-11:00AM: Abstract Number: 2102

The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria

9:00AM-11:00AM: Abstract Number: 2107

Therapeutic Response to Prednisone in Relation to Age in Polymyalgia Rheumatica: A Controlled Study

9:00AM-11:00AM: Abstract Number: 2095

Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2127

Tumor Necrosis Factor Inhibitors for Sarcoidosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].